Computationally guided high-throughput design of self-assembling drug nanoparticles

Abstract

Nanoformulations are transforming our capacity to effectively deliver and treat a myriad of conditions. However, many nanoformulation approaches still suffer from high production complexity and low drug loading. One potential solution relies on harnessing co-assembly of drugs and small molecular excipients to facilitate nanoparticle formation through solvent exchange without the need for chemical synthesis, generating nanoparticles with up to 95% drug loading. However, there is currently no understanding which of the millions of possible combinations of small molecules can result in the formation of these nanoparticles. Here we report the development of a high-throughput screening platform coupled to machine learning to enable the rapid evaluation of such nanoformulations. Our platform identified 101 novel self-assembling drug nanoparticles from 2.1 million pairings derived from 788 candidate drugs with one of 2686 excipients, spanning treatments for multiple diseases and often harnessing well-known food additives, vitamins, or approved drugs as carrier materials -with potential for accelerated approval and translation. Given their long-term stability and potential for clinical impact, we further characterize novel sorafenib-glycyrrhizin and terbinafine-taurocholic acid nanoparticles ex vivo and in vivo. We anticipate that this platform could accelerate the development of safer and more efficacious nanoformulations with high drug loadings for a wide range of therapeutics.

Machine learning predicts 3D printing performance of over 900 drug delivery systems

“…Therefore, to have a means of predicting the optimal parameters that will produce the 3D printed object with the best performance would be desirable. Machine Learning (ML) may hold the key to optimising this process [58,59]. ML is an Artificial Intelligence (AI)-based, stateof-the-art technology that enables pattern recognition from complex datasets [60][61][62][63].…”

Nanoengineering Apolipoprotein A1‐Based Immunotherapeutics

“…From these screens, “laws” on structure‐function relationships can be extracted through computational modeling methods, including machine learning. [ 128,129 ]…”

Colonic drug delivery: Formulating the next generation of colon-targeted therapeutics

“…provided by MM, and atomic visualisation enabled by MD [275]. For example, Reker et al used ML combined with MD to discover 100 novel co-aggregated solid drug nanoparticles composed of self-assembled drug-excipient combinations, two of which were successfully characterised ex vivo and in vivo [276]. This study exemplifies how the unification of advanced in silico technologies can be employed to accelerate and optimise formulation development by exploiting pre-existing big data.…”